Clinical pharmacokinetics of imatinib mesylate

被引：0
|
作者：
Levêque, D
Maloisel, F
机构：
[1] Hop Hautepierre, F-67000 Strasbourg, France
[2] Inst Bacteriol, F-67000 Strasbourg, France
[3] Hop Civil, Dept Hematol & Oncol, F-67000 Strasbourg, France
来源：
IN VIVO | 2005年 / 19卷 / 01期
关键词：
imatinib mesylate; pharmacokinetics;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The review presents the clinical pharmacokinetics of imatinib mesylate. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed.
引用
收藏
页码：77 / 84
页数：8
相关论文
共 50 条
  • [1] Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients IL-2 interferes with the pharmacokinetics of imatinib mesylate
    Pautier, Patricia
    Locher, Clara
    Robert, Caroline
    Deroussent, Alain
    Flament, Caroline
    Le Cesne, Axel
    Rey, Annie
    Bahleda, Ratislav
    Ribrag, Vincent
    Soria, Jean-Charles
    Vassal, Gilles
    Eggermont, Alexander
    Zitvogel, Laurence
    Chaput, Nathalie
    Paci, Angelo
    ONCOIMMUNOLOGY, 2013, 2 (02):
  • [2] Clinical Pharmacokinetics of Imatinib
    Bin Peng
    Peter Lloyd
    Horst Schran
    Clinical Pharmacokinetics, 2005, 44 : 879 - 894
  • [3] Clinical pharmacokinetics of imatinib
    Peng, B
    Lloyd, P
    Schran, H
    CLINICAL PHARMACOKINETICS, 2005, 44 (09) : 879 - 894
  • [4] Effect of St John's wort on imatinib mesylate pharmacokinetics
    Frye, RF
    Fitzgerald, SM
    Lagattuta, TF
    Hruska, MW
    Egorin, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (04) : 323 - 329
  • [5] Indications for imatinib mesylate therapy and clinical management
    Guilhot, F
    ONCOLOGIST, 2004, 9 (03): : 271 - 281
  • [6] Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults
    Menon-Andersen, Divya
    Mondick, John T.
    Jayaraman, Bhuvana
    Thompson, Patrick A.
    Blaney, Susan M.
    Bernstein, Mark
    Bond, Mason
    Champagne, Martin
    Fossler, Michael J.
    Barrett, Jeffrey S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 229 - 238
  • [7] Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults
    Divya Menon-Andersen
    John T. Mondick
    Bhuvana Jayaraman
    Patrick A. Thompson
    Susan M. Blaney
    Mark Bernstein
    Mason Bond
    Martin Champagne
    Michael J. Fossler
    Jeffrey S. Barrett
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 229 - 238
  • [8] Imatinib mesylate induces clinical remission in rheumatoid arthritis
    Pereira, Ivanio
    Fialho, Sonia
    Castro, Glaucio
    Zimmermann, Adriana
    JOINT BONE SPINE, 2010, 77 (04) : 372 - 373
  • [9] Effect of St. John's Wort on imatinib mesylate pharmacokinetics.
    Frye, RF
    Fitzgerald, SM
    Lagattuta, TF
    Egorin, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P96 - P96
  • [10] Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study
    Periklis Pappas
    Vasilis Karavasilis
    Evangelos Briasoulis
    Nicholas Pavlidis
    Marios Marselos
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 358 - 360
12345